As temperatures drop, many people experience dry, red, and itchy skin, a condition that often worsens in winter.

Ruxolitinib cream 1.5% was safe and effective for the treatment of children and adolescents with a 35% or greater body surface areas affected by atopic dermatitis, according to a study.Ruxolitinib ...

Long-term lebrikizumab was effective for atopic dermatitis treatment in patients who did not have adequate response to short-term treatment.

Celldex Therapeutics , Inc. (NASDAQ:CLDX), with a market capitalization of $1.72 billion, is a biopharmaceutical company focused on developing innovative therapies for challenging diseases, with its ...

Monthly tralokinumab is an effective dosing regimen for patients with atopic dermatitis who have achieved stable disease control.

Data from a retrospective multicenter study, along with a review of previous trials, supported the real-world utility of ...

AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...

Apogee Therapeutics develops therapies for inflammatory autoimmune diseases. Find out why I'm bearish on APGE stock.

Atopic dermatitis, affecting 10% to 20% of children globally, is marked by chronic inflammation and varied complications, including infection risks.

Department of Radiology, Regional Specialized Children’s Hospital, Olsztyn, Poland Dermatological Students Scientific Association, Department of Dermatology, Venereology and Allergology, Faculty of ...

This achievement further emphasises the drug’s efficacy across multiple indications, including atopic dermatitis (AD ... for competition in AD treatment and may introduce a novel therapeutic ...

Allergic dermatitis is very common in people with atopic dermatitis. Some people with atopic dermatitis sometimes get eczema from contact dermatitis as well. Both contact dermatitis and atopic ...